GLP-1 & Incretin Science

How to Read a Pharmacovigilance Signal

UKPWritten and published by UK Peptides3 min readUpdated 3 cited sources

The short answer

Disproportionality measures such as PRR and ROR describe how often an adverse event appears in a spontaneous reporting database relative to other events, not how often it occurs in people. They detect signals for investigation. They cannot estimate risk, because the database has no denominator.

Key facts

PRR
Proportional reporting ratio
ROR
Reporting odds ratio
Source
Spontaneous reporting databases (FAERS, Yellow Card)
What they measure
Disproportionate reporting
What they cannot measure
Incidence or risk
Missing element
A denominator (how many people took the drug)
Correct use
Signal detection, prompting further study

What a spontaneous reporting database is

FAERS in the United States and the Yellow Card scheme in the UK collect reports of suspected adverse reactions submitted voluntarily by clinicians, patients and manufacturers. They are enormously valuable for detecting rare events that trials are too small to find. They are also, by construction, a collection of reports rather than a study. Nobody was enrolled, nothing was randomised, and no one counted how many people took the drug without incident.

What PRR and ROR actually compute

Both compare how frequently a particular event is reported for a particular drug against how frequently it is reported for everything else in the database. A high value means this event is disproportionately represented among reports for this drug. That is a statement about the composition of a report collection. It is not a statement about how many people experienced the event.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The missing denominator

To calculate a risk you need to know how many people were exposed. A spontaneous database does not know this. If a drug is taken by ten million people and generates two hundred reports of an event, and another is taken by ten thousand and generates twenty, the crude report counts are wildly misleading, and the disproportionality measures do not fix that. They were never designed to.

Reporting is not random

Several biases push in the same direction. Newly launched drugs attract more reporting than established ones. Media attention to a possible association increases reporting of that association, sometimes dramatically. This is known as notoriety bias, and it can manufacture a signal from publicity alone. Serious events are reported more than mild ones. None of these are flaws in the system so much as properties of it, and all of them affect disproportionality values.

A worked example

A disproportionality analysis reporting a PRR of 18.9 and ROR of 19.4 for liraglutide and acute pancreatitis is frequently repeated as though it meant a nineteen-fold risk. It does not. It means reports of pancreatitis were disproportionately represented among liraglutide reports relative to the rest of the database. Whether that reflects a real elevated risk, and of what magnitude, requires a cohort study with a defined population, which is what such a signal should prompt.

What signals are for

They are the first stage of a working pharmacovigilance system, not its conclusion. A signal triggers investigation; a cohort or case-control study with a real denominator estimates risk; a regulator weighs that against benefit and acts. The MHRA's February 2026 semaglutide update is the visible end of that pipeline. Note that it came with a frequency estimate, up to 1 in 10,000, which is the sort of figure disproportionality analysis can never produce.

Quick reference

Disproportionality (PRR/ROR)Cohort study
Data sourceSpontaneous reportsDefined population
DenominatorNoneKnown
Can estimate incidenceNoYes
Can estimate riskNoYes
Vulnerable to reporting biasYes, stronglyMuch less so
Correct roleDetect signalsQuantify them

Frequently asked questions

Does a ROR of 19 mean a nineteen-fold risk?

No. It means the event was disproportionately represented among reports for that drug. Without a denominator, no risk can be calculated from it.

Are these databases useless then?

Far from it. They detect rare events trials are too small to find. The error is treating a detection tool as a measurement tool.

What is notoriety bias?

Publicity about a possible drug-event association increases reporting of that association, which can inflate disproportionality measures independently of any real change in risk.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.